Effect of “DXB-2030,” a Polyherbal Formulation, on Experimental Polycystic Ovary Syndrome Associated with Hyperandrogenism
The objective of the present study was to evaluate “DXB-2030,” a polyherbal combination of Trigonella foenum-graecum, Aloe vera, Sphaeranthus indicus, Nardostachys jatamansi, and Symplocos racemosa extracts in an experimental model of testosterone propionate (TP), induced polycystic ovary syndrome (...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Advances in Pharmacological Sciences |
| Online Access: | http://dx.doi.org/10.1155/2019/8272850 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563857083596800 |
|---|---|
| author | Mohammed Azeemuddin Suryakanth D. Anturlikar Mallappa Onkaramurthy Mirza R. Baig Basti K. Ashok Raghavendra P. Rao Mohamed Rafiq Paramesh Rangesh |
| author_facet | Mohammed Azeemuddin Suryakanth D. Anturlikar Mallappa Onkaramurthy Mirza R. Baig Basti K. Ashok Raghavendra P. Rao Mohamed Rafiq Paramesh Rangesh |
| author_sort | Mohammed Azeemuddin |
| collection | DOAJ |
| description | The objective of the present study was to evaluate “DXB-2030,” a polyherbal combination of Trigonella foenum-graecum, Aloe vera, Sphaeranthus indicus, Nardostachys jatamansi, and Symplocos racemosa extracts in an experimental model of testosterone propionate (TP), induced polycystic ovary syndrome (PCOS) in female rats. Thirty animals were divided into 3 groups of 10 each; group 1 served as normal control; group 2 was administered with TP and served as positive control; along with TP, group 3 was treated with “DXB-2030” at a dose of 100 mg/kg p.o., for 60 days. At the end of the study period, the animals were subjected for the estimation of serum testosterone levels, oral glucose tolerance test (OGTT), weight of the ovaries, estrous cycle, and histopathological evaluation. An in vitro assay on GLUT4 expression was carried out to understand the effect of “DXB-2030” on insulin resistance. Results showed that treatment with “DXB-2030” reversed the TP-induced changes by increasing the GLUT4 expression and decreasing the body weight, testosterone levels, AUC of glucose in OGTT, and the cystic follicles of the ovaries, thus indicating its beneficial effect in PCOS by ameliorating the metabolic dysfunction and reproductive impairment, which are the pathophysiological conditions associated with PCOS. From the results obtained, it can be concluded that “DXB-2030” was effective in the management of experimental PCOS and hence may be recommended in the treatment of PCOS. |
| format | Article |
| id | doaj-art-977cec7a82cc4a329c4af2fd7bfde3c6 |
| institution | Kabale University |
| issn | 1687-6334 1687-6342 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Pharmacological Sciences |
| spelling | doaj-art-977cec7a82cc4a329c4af2fd7bfde3c62025-02-03T01:12:26ZengWileyAdvances in Pharmacological Sciences1687-63341687-63422019-01-01201910.1155/2019/82728508272850Effect of “DXB-2030,” a Polyherbal Formulation, on Experimental Polycystic Ovary Syndrome Associated with HyperandrogenismMohammed Azeemuddin0Suryakanth D. Anturlikar1Mallappa Onkaramurthy2Mirza R. Baig3Basti K. Ashok4Raghavendra P. Rao5Mohamed Rafiq6Paramesh Rangesh7Discovery Sciences Group, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, IndiaDiscovery Sciences Group, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, IndiaDiscovery Sciences Group, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, IndiaDepartment of Microbiology & Toxicology R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, IndiaDiscovery Sciences Group, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, IndiaDiscovery Sciences Group, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, IndiaDiscovery Sciences Group, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, IndiaChief Scientific Officer, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, IndiaThe objective of the present study was to evaluate “DXB-2030,” a polyherbal combination of Trigonella foenum-graecum, Aloe vera, Sphaeranthus indicus, Nardostachys jatamansi, and Symplocos racemosa extracts in an experimental model of testosterone propionate (TP), induced polycystic ovary syndrome (PCOS) in female rats. Thirty animals were divided into 3 groups of 10 each; group 1 served as normal control; group 2 was administered with TP and served as positive control; along with TP, group 3 was treated with “DXB-2030” at a dose of 100 mg/kg p.o., for 60 days. At the end of the study period, the animals were subjected for the estimation of serum testosterone levels, oral glucose tolerance test (OGTT), weight of the ovaries, estrous cycle, and histopathological evaluation. An in vitro assay on GLUT4 expression was carried out to understand the effect of “DXB-2030” on insulin resistance. Results showed that treatment with “DXB-2030” reversed the TP-induced changes by increasing the GLUT4 expression and decreasing the body weight, testosterone levels, AUC of glucose in OGTT, and the cystic follicles of the ovaries, thus indicating its beneficial effect in PCOS by ameliorating the metabolic dysfunction and reproductive impairment, which are the pathophysiological conditions associated with PCOS. From the results obtained, it can be concluded that “DXB-2030” was effective in the management of experimental PCOS and hence may be recommended in the treatment of PCOS.http://dx.doi.org/10.1155/2019/8272850 |
| spellingShingle | Mohammed Azeemuddin Suryakanth D. Anturlikar Mallappa Onkaramurthy Mirza R. Baig Basti K. Ashok Raghavendra P. Rao Mohamed Rafiq Paramesh Rangesh Effect of “DXB-2030,” a Polyherbal Formulation, on Experimental Polycystic Ovary Syndrome Associated with Hyperandrogenism Advances in Pharmacological Sciences |
| title | Effect of “DXB-2030,” a Polyherbal Formulation, on Experimental Polycystic Ovary Syndrome Associated with Hyperandrogenism |
| title_full | Effect of “DXB-2030,” a Polyherbal Formulation, on Experimental Polycystic Ovary Syndrome Associated with Hyperandrogenism |
| title_fullStr | Effect of “DXB-2030,” a Polyherbal Formulation, on Experimental Polycystic Ovary Syndrome Associated with Hyperandrogenism |
| title_full_unstemmed | Effect of “DXB-2030,” a Polyherbal Formulation, on Experimental Polycystic Ovary Syndrome Associated with Hyperandrogenism |
| title_short | Effect of “DXB-2030,” a Polyherbal Formulation, on Experimental Polycystic Ovary Syndrome Associated with Hyperandrogenism |
| title_sort | effect of dxb 2030 a polyherbal formulation on experimental polycystic ovary syndrome associated with hyperandrogenism |
| url | http://dx.doi.org/10.1155/2019/8272850 |
| work_keys_str_mv | AT mohammedazeemuddin effectofdxb2030apolyherbalformulationonexperimentalpolycysticovarysyndromeassociatedwithhyperandrogenism AT suryakanthdanturlikar effectofdxb2030apolyherbalformulationonexperimentalpolycysticovarysyndromeassociatedwithhyperandrogenism AT mallappaonkaramurthy effectofdxb2030apolyherbalformulationonexperimentalpolycysticovarysyndromeassociatedwithhyperandrogenism AT mirzarbaig effectofdxb2030apolyherbalformulationonexperimentalpolycysticovarysyndromeassociatedwithhyperandrogenism AT bastikashok effectofdxb2030apolyherbalformulationonexperimentalpolycysticovarysyndromeassociatedwithhyperandrogenism AT raghavendraprao effectofdxb2030apolyherbalformulationonexperimentalpolycysticovarysyndromeassociatedwithhyperandrogenism AT mohamedrafiq effectofdxb2030apolyherbalformulationonexperimentalpolycysticovarysyndromeassociatedwithhyperandrogenism AT parameshrangesh effectofdxb2030apolyherbalformulationonexperimentalpolycysticovarysyndromeassociatedwithhyperandrogenism |